Anti-Mouse/Human/Rat Osteopontin [Clone 103D6] — Purified in vivo PLATINUM™ Functional Grade

Recombinant mouse OPN protein

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

103D6 activity is directed against mouse, human, and rat osteopontin, also known as secreted phosphoprotein 1 (SPP1).

Osteopontin is a phosphorylated glycoprotein¹ that regulates bone formation, bone tissue remodeling, and promotes osteogenic differentiation of mesenchymal stem cells². Osteopontin also inhibits adipogenic differentiation, can induce angiogenesis, and promotes leukocyte adhesion. Osteopontin performs its regulatory roles by interacting with integrins to activate downstream signaling pathways. In cancer, increased levels of osteopontin are associated with migration, invasion, and poor prognosis. Osteopontin promotes tumor development by activating the PI3K/pAkt/NF-κB pathway when interacting with the αvβ3 integrin and can promote cancer invasion when interacting with CD44. Osteopontin is thus a target for the development of cancer treatments, including transcription and translation inhibitors as well as blockade by immunotherapy.

103D6 was generated by immunizing C57BL/6 mice with recombinant osteopontin protein¹. Mice with the highest osteopontin antibody titer, as determined by ELISA, were selected for spleen cell electro-fusion with SP2/0 myeloma cells. Fused cells were screened by ELISA with osteopontin protein and then by T cell proliferation rescue assay in anti-CD3/CD28/osteopontin- coated plates.

103D6 is a neutralizing antibody that inhibits colonic tumor growth in vivo and increases tumor- specific cytotoxic T lymphocyte effector function¹.

Osteopontin is a secreted protein found in bone that is also expressed intracellularly in other tissues, including cardiac fibroblasts, dendritic cells, macrophages, smooth muscle, endothelial cells, kidney, and brain. In cancer, osteopontin can also be expressed in tumor cells, myeloid cells, and innate lymphoid cells. Additionally, osteopontin is elevated in human cancer patient peripheral blood.

CD44
integrins (αVβ3)

1 Klement JD, Poschel DB, Lu C, et al. Cancers (Basel). 13(5):1006. 2021.
2 Xu W, Bi Z, Lu L, et al. Oncol Rep. 54(5):136. 2025.